Floatz logo

Egfrt/19-28Z/Il-12 Car T-Lymphocytes

Philadelphia-Positive ALL

Memorial Sloan Kettering Cancer CenterCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

34 Active assets in the Philadelphia-Positive ALL cohort.

Asset / SponsorPhaseRating
Nilotinib
The University of Hong Kong
Phase 2BBB
Cytosin-Arabinosid
Novartis Pharmaceuticals
Phase 3BBB
Blinatumomab
Novartis Pharmaceuticals
Phase 3BBB
METHOTREXATE
Novartis Pharmaceuticals
Phase 3BB
Imatinib
The University of Hong Kong
Phase 3BB

View all 50 →

Same molecule, other indications

Egfrt/19-28Z/Il-12 Car T-Lymphocytes is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CC
Indicative ·
43 / 100
View asset →
acute lymphoblastic leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →